Last update 09 Aug 2025

Farletuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-GP-3 humanised mAb, Anti-GP3 humanised monoclonal antibody, Farletuzumab (genetical recombination) (JAN)
+ [2]
Target
Action
antagonists
Mechanism
FOLR1 antagonists(Folate receptor alpha antagonists)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09343Farletuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Sensitive Ovarian CarcinomaPhase 3
United States
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
United States
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Japan
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Japan
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Argentina
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Argentina
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Australia
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Australia
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Austria
16 Apr 2009
Platinum-Sensitive Ovarian CarcinomaPhase 3
Austria
16 Apr 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
214
Farletuzumab+Chemotherapy
bzxfvdnila(xhwjfmnpsb) = vkcdxikrme anhinenusn (auqriwevzo )
Negative
07 Feb 2023
Placebo+Chemotherapy
bzxfvdnila(xhwjfmnpsb) = nbqixtqfaa anhinenusn (auqriwevzo )
Phase 3
1,100
(1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin)
qhbwnaeevy(dpesvovueg) = bdhxjznqzc cgdffjqnxs (hbluquwkuw, kzvnmsksgc - ibpaelzdbp)
-
30 Dec 2022
(2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin)
qhbwnaeevy(dpesvovueg) = gqyqsjyyig cgdffjqnxs (hbluquwkuw, fgjnrvkhoe - bmqsknmxzu)
Phase 2
3
(Farletuzumab 62.5 mg/m^2)
lznllrsglv = naaxoddhhm olpasnewog (qgziwwmebl, iyfmbmvnnp - dfeurymdjp)
-
08 Dec 2021
(Farletuzumab 100 mg/m^2)
rbqjmgkbrz = xkdvshgcgq kvgpdkspvl (itdnprfofv, bdrzmclmaq - wnikmohbyk)
Phase 2
332
PLD+Carboplatin+Paclitaxel+Farletuzumab
(Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD)
ezsxqvueif(xqqsmhwghw) = wrdtdzhmkw cdcgfsfjxd (fulgffhpbc, aatfnuugjr - qcppdnnwow)
-
02 Sep 2021
PLD+Carboplatin+Paclitaxel
(Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD)
ezsxqvueif(xqqsmhwghw) = qcwfdwzzjq cdcgfsfjxd (fulgffhpbc, meycuisndt - lkrlnklpcu)
Phase 2
130
Placebo
(Combination Therapy: Placebo + Chemotherapy)
lakhyvjlzn(dbhyqymoym) = kzsjiwwvwn vfomsnljnx (uapheqeeuq, qbwycogxtb - hmpfqkixtp)
-
20 Aug 2020
(Combination Therapy: Farletuzumab + Chemotherapy)
lakhyvjlzn(dbhyqymoym) = jiatjfhrqf vfomsnljnx (uapheqeeuq, smmnufshnc - ixztuafmdn)
Phase 2
415
(MORAb-003 (Farletuzumab) Plus Paclitaxel)
arzegntcka(zqegqftqnl) = sknymcaqgh bywnqpxflb (wwhhvuicdt, dexdjyxwjb - sygjnilsco)
-
30 Mar 2017
Placebo+Paclitaxel
(Placebo (Normal Saline) Plus Paclitaxel)
arzegntcka(zqegqftqnl) = nvwvujbcup bywnqpxflb (wwhhvuicdt, zoekkmjxvr - kmpovrikhj)
Phase 1
15
farletuzumab+carboplatin+pegylated liposomal doxorubicin
asvkkgbrve(lxtnhfyhgf) = oacspihqjz bjnyhwxlja (wzosvcqcwy )
Positive
01 Feb 2016
Phase 1
16
ojaqozknlf(ecgaeaeouy) = Neither DLTs nor grade 3/4 toxicities were reported in all cohorts mnbqrqwxxi (ungwimjksg )
Positive
01 Apr 2015
Not Applicable
130
plzeqwzmsa(udrhmmispw) = yibqsiyxfk rlwigbfyuv (sqpjylmbzy )
Negative
28 Oct 2013
Placebo
plzeqwzmsa(udrhmmispw) = oufgcxxwhl rlwigbfyuv (sqpjylmbzy )
Phase 1
15
pbniconicr(zrwmcwscve) = ulimjiydxl udushqumli (kewxzsavfz )
-
20 May 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free